Exhibit 99.1

DuPont Delivers Strong Results in Second Quarter; Increases 2011 Earnings Guidance
Sales Gains in all Segments & Regions and Danisco Acquisition Underpin Growth Outlook

Highlights:

·                  Second-quarter 2011 earnings were $1.37 per share, up 17 percent versus $1.17 per share in the prior year, excluding significant items from both periods (see Schedule B). Reported second-quarter 2011 earnings were $1.29 per share, including significant item charges of $.08 per share related to the acquisition. Reported second-quarter 2010 earnings were $1.26 per share.

·                  Sales increased 19 percent to $10.3 billion with 11 percent higher local prices, 2 percent higher sales volume, 3 percent currency benefit and a 3 percent net increase from portfolio changes.  Sales in developing markets grew 29 percent and represent 30 percent of total sales.

·                  Strong performances in Agriculture, Performance Chemicals and Safety & Protection, and the acquisition of Danisco contributed to a 20 percent increase in segment pre-tax operating income, excluding significant items.

·                  The company is on track versus its full-year 2011 productivity targets for fixed costs and working capital.  Year-to-date fixed cost productivity totals more than $180 million.

·                  The company increased its full-year 2011 earnings outlook, excluding significant items, to a range of $3.90 to $4.05 per share.  The increase reflects strong second-quarter results, the expectation for continued global economic growth and about $.05 per share full-year impact from Danisco on an underlying basis.   Prior guidance was a range of $3.65 to $3.85 per share, excluding the impact of Danisco.

“Our strong second-quarter sales growth across all segments and regions resulted from consistent global execution and customer-focused innovation,” said DuPont Chair and CEO Ellen Kullman.  “We are increasing our earnings outlook for 2011 based on strong performance year—to-date and confidence in our business plans for the second half of the year.  Longer term, we expect additional compelling growth opportunities across our businesses stemming from science-powered innovations and collaboration, including the integration of Danisco’s world-class enzymes, fermentation and specialty food ingredients capabilities with DuPont’s strong industrial biosciences and nutrition & health offerings.”

Global Consolidated Sales and Net Income

Second-quarter 2011 consolidated net sales of $10.3 billion were 19 percent higher than the prior year reflecting 11 percent higher local prices, 2 percent higher volume, 3 percent favorable currency effect and a 3 percent net increase from portfolio changes.  The table below shows regional sales and variances versus the second quarter 2010.

* Europe, Middle East & Africa

Second-quarter 2011 net income attributable to DuPont increased 5 percent to $1,218 million versus $1,159 million in 2010. Excluding significant items, net income attributable to DuPont of $1,299 million increased $227 million, or 21 percent, from $1,072 million in the second quarter 2010.  The increase principally reflects higher selling prices, increased sales volume and currency benefit, partly offset by higher raw material, energy, and freight costs.

2

Earnings Per Share

The table below shows year-over-year earnings per share (EPS) variances for the second quarter.

EPS  ANALYSIS

3

Business Segment Performance

The table below shows second quarter 2011 segment sales and related variances versus the prior year.

* Segment sales include transfers

Segment pre-tax operating income (PTOI) for second quarter 2011 was $1,943 million compared to second quarter 2010 PTOI of $1,655 million.   Excluding significant items, PTOI was $1,993 million, a 20 percent improvement from prior year, as shown in the table below.

* See schedules B and C for listing of significant items and their impact by segment.

4

In view of the company’s expanded business portfolio following the Danisco acquisition, two new reportable segments have been added: Industrial Biosciences and Nutrition & Health.  The Industrial Biosciences segment includes Danisco’s enzyme business and DuPont™ Sorona® and Bio-PDOTM businesses, previously reported in Other.  The new Nutrition & Health segment contains Danisco’s food ingredients business and DuPont’s Nutrition & Health business previously reported as part of the Agriculture & Nutrition segment.  The former Agriculture & Nutrition segment, now renamed Agriculture, includes the seed and crop protection businesses.  The following is a summary of business results for each of the company’s reportable segments, comparing second quarter 2011 with second quarter 2010, for sales and PTOI excluding significant items. References to selling price are on a U.S. dollar basis, including the impact of currency.

Agriculture — Sales of $3.0 billion were up $264 million, or 10 percent, reflecting 6 percent price gains and 4 percent volume gains.  Pioneer seed growth was led by strong market performance in North America spanning volume, price and portfolio gains.   Crop Protection sales increased across all product lines more than offsetting the impact of divested businesses.  PTOI for the quarter of $826 million grew 11 percent on higher sales, partly offset by the impact of portfolio changes.

First-half sales of $6.5 billion grew 15 percent with 9 percent higher volume, 5 percent price gains and 1 percent favorable impact of portfolio changes.   Pioneer seed business delivered volume and price gains in North America and Europe.  Crop Protection sales growth was underpinned by continued strong Rynaxypyr® sales, solid herbicide and picoxystrobin fungicide growth, partly offset by the impact of divested businesses.  PTOI for the first half of $1.9 billion grew 16 percent on higher sales.

Electronics & Communications — Sales of $891 million were up 36 percent, with 27 percent higher selling prices, primarily pass-through of metals prices, and 9 percent higher volume.  Volume growth was fueled by strong demand for photovoltaics and consumer electronics in Asia Pacific.  PTOI of $103 million decreased $5 million reflecting increased spending for photovoltaics growth initiatives and extreme volatility of metals pricing which reduced PTOI by about $20 million.

Industrial Biosciences — Sales of $123 million and PTOI of $10 million primarily reflect the acquisition of Danisco’s enzyme business.  PTOI included approximately $2 million of amortization expense associated with the fair value step-up of intangible assets acquired as part of the acquisition.

Nutrition & Health — Sales of $486 million were up $189 million, or 64 percent, with a 58 percent increase from the acquisition of Danisco’s food ingredients business, 4 percent higher selling prices and 2 percent volume growth.  PTOI of $38 million increased $22 million, primarily due to the acquisition.  PTOI included approximately $7 million of amortization expense associated with the fair value step-up of intangible assets acquired as part of the acquisition.

Performance Chemicals — Sales of $2.0 billion were up 27 percent, with 28 percent higher selling prices and 1 percent lower volume.  Sales increased substantially across all major regions.  Higher selling prices stemmed from strong global demand for titanium dioxide, refrigerants, fluoroproducts and industrial chemicals, and more than offset raw material increases.  Lower volume reflects weather-related supply disruptions in industrial chemicals.  PTOI was $503 million, increasing $229 million on strong sales performance.

Performance Coatings — Sales of $1.1 billion were up 15 percent, with 14 percent higher selling prices and 1 percent higher volume.  Higher selling prices reflect pricing actions across all market segments to offset higher raw material costs along with a favorable currency impact. Strong demand continued in industrial coatings, particularly in North American heavy-duty truck markets.  PTOI of $73 million decreased slightly as higher sales were offset by higher raw material, energy and freight costs.

Performance Materials — Sales of $1.7 billion were up 11 percent, with 14 percent higher selling prices, partially offset by 2 percent lower volume and a 1 percent reduction from a portfolio change.  Ongoing demand in electronic, packaging and automotive markets led to favorable pricing in all regions.  Lower

5

volume reflects supply constraints due to production outages, as well as supply chain disruptions as a result of the Japan earthquake.  PTOI of $254 million decreased slightly due to the absence of a $27 million benefit from a gain on the sale of a business and an insurance recovery in the prior year and lower volume, partially offset by higher selling prices.

Safety & Protection — Sales of $1.0 billion were up 21 percent, with an 8 percent increase from a portfolio change as a result of the MECS acquisition, 7 percent higher volume and 6 percent higher selling prices.  Higher volume reflects continued growth from increased demand for aramid and nonwoven products in industrial and public sector markets across all major regions.  Higher selling prices primarily reflect pricing actions taken to offset increases in raw material costs.  PTOI of $143 million increased significantly, primarily driven by the portfolio change and a favorable currency impact, partially offset by higher spending for the Kevlar® expansion at Cooper River.

Additional information is available on the DuPont Investor Center website at www.dupont.com.

Outlook

The company increased its full-year 2011 earnings outlook, excluding significant items, to a range of $3.90 to $4.05 per share.  The increase reflects strong second-quarter results, the expectation for continued global economic growth and about $.05 per share full-year operating earnings from Danisco on an underlying basis.   Prior guidance was a range of $3.65 to $3.85 per share, excluding the impact of Danisco.

The company’s estimate for the impact of the Danisco acquisition on full-year reported earnings is now a reduction of $.18 to $.29 per share, versus the previous estimate of a $.30 to $.45 per share reduction. The current view is based on anticipated full-year Danisco operating earnings of about $.05 per share and significant item charges related to the acquisition estimated to be $.23 to $.34 per share. In addition to these Danisco charges, the company expects a $.03 per share significant item charge in the third quarter associated with a licensing agreement.

Use of Non-GAAP Measures

Management believes that certain non-GAAP measurements are meaningful to investors because they provide insight with respect to ongoing operating results of the company.  Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance.  Reconciliations of non-GAAP measures to GAAP are provided in schedules C and D.

DuPont (www.dupont.com) is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 90 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates” or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company’s growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control.  Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; inability to protect and enforce the company’s intellectual property rights; and integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.  The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

#   #   #

7/28/11

6

E. I. du Pont de Nemours and Company

Consolidated Income Statements

(Dollars in millions, except per share amounts)

SCHEDULE A

(a) See Schedule B for detail of significant items.

7

E. I. du Pont de Nemours and Company

Condensed Consolidated Balance Sheets

(Dollars in millions, except per share amounts)

SCHEDULE A (continued)

8

E. I. du Pont de Nemours and Company

Condensed Consolidated Statement of Cash Flows

(Dollars in millions)

SCHEDULE A (continued)

9

E. I. du Pont de Nemours and Company

Schedule of Significant Items

(Dollars in millions, except per share amounts)

SCHEDULE B

SIGNIFICANT ITEMS

See Schedule C for detail by segment.

10

E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)

SCHEDULE C

(1)   Sales for the reporting segments include transfers.

11

E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)

SCHEDULE C (continued)

12

E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions, except per share amounts)

SCHEDULE D

Summary of Earnings Comparisons